Reuters
2022.08.03 21:12

Sorrento Completes Successfully SAD Study And Initiates MAD Phase 1 Study With STI-1558

Aug 3 (Reuters) - Sorrento Therapeutics Inc:

Aug 3 (Reuters) - Sorrento Therapeutics Inc (SRNE.O) :

  • SORRENTO COMPLETES SUCCESSFULLY THE SAD STUDY AND INITIATES THE MAD PHASE 1 STUDY WITH STI-1558, AN ORAL M(PRO) INHIBITOR AS A STANDALONE TREATMENT AND PREVENTION OF COVID-19 WITHOUT THE RITONAVIR AS BOOSTER

  • SORRENTO THERAPEUTICS INC- INITIATION OF MULTIPLE ASCENDING DOSE (MAD) PORTION OF STI-1558 STUDY HAS BEEN INITIATED

  • SORRENTO THERAPEUTICS INC- PRELIMINARY OVERALL SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS SHOWED THAT THERE WERE NO SERIOUS AES OR SEVERE TEAES

The copyright of this article belongs to the original author/organization.
The current content only represents the author’s point of view, and has nothing to do with the position of Longbridge. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by Longbridge, please contact: editorial@longbridge.global

Like